正在服用钠-葡萄糖协同转运蛋白2抑制剂的患者必须保持水合状态。 - Suppr | 超能文献

Hydration must be maintained in patients taking sodium glucose cotransporter 2 inhibitors.

作者信息

Auersperg Edward V

机构信息

Ridge Meadows Hospital, 11666 Laity Street, Maple Ridge, BC, Canada V2X 7G5.

出版信息

BMJ. 2019 Feb 6;364:l547. doi: 10.1136/bmj.l547.

DOI:10.1136/bmj.l547

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Hydration must be maintained in patients taking sodium glucose cotransporter 2 inhibitors.正在服用钠-葡萄糖协同转运蛋白2抑制剂的患者必须保持水合状态。

BMJ. 2019 Feb 6;364:l547. doi: 10.1136/bmj.l547.

2

Letter by Koh Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".科关于文章《钠-葡萄糖协同转运蛋白2抑制剂起始治疗患者与其他降糖药物相比心力衰竭和死亡风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）》的信

Circulation. 2018 Feb 27;137(9):984-985. doi: 10.1161/CIRCULATIONAHA.117.030650.

3

Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".泰格特迈尔和卡尔施泰特就文章《钠-葡萄糖协同转运蛋白2抑制剂起始治疗患者与其他降糖药物相比心力衰竭和死亡风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）》所写的信

Circulation. 2018 Feb 27;137(9):986-987. doi: 10.1161/CIRCULATIONAHA.117.031193.

4

Letter by Tampaki et al Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".坦帕基等人就文章《与其他降糖药物相比，起始使用钠-葡萄糖协同转运蛋白2抑制剂的患者发生心力衰竭和死亡的风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）》所写的信

Circulation. 2018 Feb 27;137(9):982-983. doi: 10.1161/CIRCULATIONAHA.117.030339.

5

Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".科西博罗德等人对关于“与其他降糖药物相比，起始使用钠-葡萄糖协同转运蛋白2抑制剂的患者心力衰竭和死亡风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）”一文的信件的回复

Circulation. 2018 Feb 27;137(9):989-991. doi: 10.1161/CIRCULATIONAHA.117.031847.

6

Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist".马修斯等人就“钠葡萄糖协同转运蛋白2抑制剂对心血管结局的类效应：对心血管疾病专科医生的启示”一文所写的信。

Circulation. 2018 Aug 7;138(6):660-661. doi: 10.1161/CIRCULATIONAHA.118.035717.

7

Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor.钠-葡萄糖协同转运蛋白2抑制剂所致正常血糖性酮症酸中毒

Am J Ther. 2018 Sep/Oct;25(5):e590-e591. doi: 10.1097/MJT.0000000000000602.

8

Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂卡格列净致 1 型糖尿病患者糖尿病酮症酸中毒

Diabetes Care. 2016 Apr;39(4):532-8. doi: 10.2337/dc15-1995.

9

Fracture Risk After Initiation of Use of Canagliflozin.开始使用卡格列净后的骨折风险。

Ann Intern Med. 2019 Jul 2;171(1):80. doi: 10.7326/L19-0320.

10

Fracture Risk After Initiation of Use of Canagliflozin.使用卡格列净起始治疗后的骨折风险

Ann Intern Med. 2019 Jul 2;171(1):79-80. doi: 10.7326/L19-0319.

引用本文的文献

1

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).托格列净在日本2型糖尿病患者中的安全性和有效性：长期上市后研究（J-STEP/LT）24个月中期分析结果

J Diabetes Investig. 2020 Jul;11(4):906-916. doi: 10.1111/jdi.13233. Epub 2020 Mar 15.